Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

HIV competition dynamics over sexual networks: first comer advantage conserves founder effects.

Ferdinandy B, Mones E, Vicsek T, Müller V.

PLoS Comput Biol. 2015 Feb 5;11(2):e1004093. doi: 10.1371/journal.pcbi.1004093. eCollection 2015 Feb.

2.

Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide Trial.

Redd AD, Mullis CE, Wendel SK, Sheward D, Martens C, Bruno D, Werner L, Garrett NJ, Abdool Karim Q, Williamson C, Porcella SF, Quinn TC, Abdool Karim SS.

J Clin Microbiol. 2014 Mar;52(3):844-8. doi: 10.1128/JCM.03143-13. Epub 2013 Dec 26.

3.

Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort.

Bartha I, Assel M, Sloot PM, Zazzi M, Torti C, Schülter E, De Luca A, Sönnerborg A, Abecasis AB, Van Laethem K, Rosi A, Svärd J, Paredes R, van de Vijver DA, Vandamme AM, Müller V.

BMC Infect Dis. 2013 Nov 12;13:537. doi: 10.1186/1471-2334-13-537.

4.

HIV-1 superinfection occurs less frequently than initial infection in a cohort of high-risk Kenyan women.

Ronen K, McCoy CO, Matsen FA, Boyd DF, Emery S, Odem-Davis K, Jaoko W, Mandaliya K, McClelland RS, Richardson BA, Overbaugh J.

PLoS Pathog. 2013;9(8):e1003593. doi: 10.1371/journal.ppat.1003593. Epub 2013 Aug 29.

5.

Frequency and implications of HIV superinfection.

Redd AD, Quinn TC, Tobian AA.

Lancet Infect Dis. 2013 Jul;13(7):622-8. doi: 10.1016/S1473-3099(13)70066-5. Epub 2013 May 31. Review.

6.

A Multi-Vector, Multi-Envelope HIV-1 Vaccine.

Hurwitz JL, Zhan X, Brown SA, Bonsignori M, Stambas J, Lockey TD, Jones B, Surman S, Sealy R, Freiden P, Branum K, Slobod KS.

J Pediatr Pharmacol Ther. 2007 Apr;12(2):68-76. doi: 10.5863/1551-6776-12.2.68.

7.

The rates of HIV superinfection and primary HIV incidence in a general population in Rakai, Uganda.

Redd AD, Mullis CE, Serwadda D, Kong X, Martens C, Ricklefs SM, Tobian AA, Xiao C, Grabowski MK, Nalugoda F, Kigozi G, Laeyendecker O, Kagaayi J, Sewankambo N, Gray RH, Porcella SF, Wawer MJ, Quinn TC.

J Infect Dis. 2012 Jul 15;206(2):267-74. doi: 10.1093/infdis/jis325. Epub 2012 Jun 5.

8.

A gp41-based heteroduplex mobility assay provides rapid and accurate assessment of intrasubtype epidemiological linkage in HIV type 1 heterosexual transmission Pairs.

Manigart O, Boeras DI, Karita E, Hawkins PA, Vwalika C, Makombe N, Mulenga J, Derdeyn CA, Allen S, Hunter E.

AIDS Res Hum Retroviruses. 2012 Dec;28(12):1745-55. doi: 10.1089/AID.2012.0023. Epub 2012 Jul 3.

9.

Timing and source of subtype-C HIV-1 superinfection in the newly infected partner of Zambian couples with disparate viruses.

Kraft CS, Basu D, Hawkins PA, Hraber PT, Chomba E, Mulenga J, Kilembe W, Khu NH, Derdeyn CA, Allen SA, Manigart O, Hunter E.

Retrovirology. 2012 Mar 20;9:22. doi: 10.1186/1742-4690-9-22.

10.

Identification of HIV superinfection in seroconcordant couples in Rakai, Uganda, by use of next-generation deep sequencing.

Redd AD, Collinson-Streng A, Martens C, Ricklefs S, Mullis CE, Manucci J, Tobian AA, Selig EJ, Laeyendecker O, Sewankambo N, Gray RH, Serwadda D, Wawer MJ, Porcella SF, Quinn TC; Rakai Health Sciences Program..

J Clin Microbiol. 2011 Aug;49(8):2859-67. doi: 10.1128/JCM.00804-11. Epub 2011 Jun 22. Erratum in: J Clin Microbiol. 2013 Aug;51(8):2805.

11.

ABC for people with HIV: responses to sexual behaviour recommendations among people receiving antiretroviral therapy in Jinja, Uganda.

Allen C, Mbonye M, Seeley J, Birungi J, Wolff B, Coutinho A, Jaffar S.

Cult Health Sex. 2011 May;13(5):529-43. doi: 10.1080/13691058.2011.558593.

12.

Polyvalent AIDS vaccines.

Lu S, Grimes Serrano JM, Wang S.

Curr HIV Res. 2010 Dec;8(8):622-9. Review.

13.

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Brown SA, Surman SL, Sealy R, Jones BG, Slobod KS, Branum K, Lockey TD, Howlett N, Freiden P, Flynn P, Hurwitz JL.

Viruses. 2010 Feb 1;2(2):435-467.

14.

SHIV infection protects against heterologous pathogenic SHIV challenge in macaques: a gold-standard for HIV-1 vaccine development?

Sealy R, Zhan X, Lockey TD, Martin L, Blanchard J, Traina-Dorge V, Hurwitz JL.

Curr HIV Res. 2009 Sep;7(5):497-503.

15.

HIV-1 vaccine design: harnessing diverse lymphocytes to conquer a diverse pathogen.

Surman SL, Sealy R, Jones BG, Hurwitz JL.

Hum Vaccin. 2009 Apr;5(4):268-71. Review.

16.

Multiple-infection and recombination in HIV-1 within a longitudinal cohort of women.

Templeton AR, Kramer MG, Jarvis J, Kowalski J, Gange S, Schneider MF, Shao Q, Zhang GW, Yeh MF, Tsai HL, Zhang H, Markham RB.

Retrovirology. 2009 Jun 3;6:54. doi: 10.1186/1742-4690-6-54.

17.

HIV-1 superinfection in the antiretroviral therapy era: are seroconcordant sexual partners at risk?

Campbell MS, Gottlieb GS, Hawes SE, Nickle DC, Wong KG, Deng W, Lampinen TM, Kiviat NB, Mullins JI.

PLoS One. 2009 May 28;4(5):e5690. doi: 10.1371/journal.pone.0005690.

18.

Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine.

Sealy R, Slobod KS, Flynn P, Branum K, Surman S, Jones B, Freiden P, Lockey T, Howlett N, Hurwitz JL.

Int Rev Immunol. 2009;28(1):49-68. doi: 10.1080/08830180802495605. Review.

19.

Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate.

Yeh WW, Jaru-Ampornpan P, Nevidomskyte D, Asmal M, Rao SS, Buzby AP, Montefiori DC, Korber BT, Letvin NL.

J Virol. 2009 Mar;83(6):2686-96. doi: 10.1128/JVI.02237-08. Epub 2009 Jan 7. Erratum in: J Virol. 2009 May;83(10):5293.

20.

Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses.

Blish CA, Dogan OC, Derby NR, Nguyen MA, Chohan B, Richardson BA, Overbaugh J.

J Virol. 2008 Dec;82(24):12094-103. doi: 10.1128/JVI.01730-08. Epub 2008 Oct 8.

Supplemental Content

Support Center